Researchers assess safety of conditionally immortalized cells for bioartificial kidney application

NewsGuard 100/100 Score

Here, the research team assessed the safety of conditionally immortalized proximal tubule epithelial cells for bioartificial kidney application, by using in vitro assays and athymic nude rats.

They demonstrate that these cells do not possess key properties of oncogenically transformed cells, including anchorage-independent growth, lack of contact inhibition and apoptosis-resistance.

Taken together, this study lays an important foundation towards bioartificial kidney development by confirming the safety of the cell line intended for incorporation.

Dr. Rosalinde Masereeuw from the Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands said, "End-stage kidney disease represents irreversible kidney failure through a variety of causes."

Human primary proximal tubule epithelial cells have a limited life span in vitro and presenting risks, such as functional changes occurring upon culturing as well as dedifferentiation and senescence of cells.

Issues related to the use of animal-derived cells in BAK are safety concerns compromising approval for clinical application and species differences in cell behavior.

Due to the expression of temperature-sensitive SV40T, cells can be expanded at permissive temperature of 33 C and differentiated into mature cells at non-permissive temperature of 37 C.

With this cell line the authors demonstrated the capacity of an efficient removal of uremic toxins when cells are cultured on hollow fiber membranes , thereby creating fully functional kidney tubules.

Finally, they evaluated cell transforming properties and tumorigenic potential in vivo to gain more insight into safety and suitability of these cells for applications in renal replacement therapies.

The Masereeuw Research team concluded,

By showing that ci PTEC-OAT1 do not portray fundamental characteristics of oncogenically transformed cells, do not present negative consequences of viral transductions and genomic transgene integrations, such as insertional mutagenesis, nor possess tumorigenic capacity in vivo, the present study lays an important foundation towards validating the safety of a conditionally immortalized cell line for clinical application as cell-based renal replacement therapy."

Source:
Journal reference:

Mihajlovic, M., et al. (2019) Safety evaluation of conditionally immortalized cells for renal replacement therapy. Oncotarget. doi.org/10.18632/oncotarget.27152.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study reveals potential cellular mechanism behind cognitive decline in Alzheimer's